INN monograph
Aceclofenac / Trypsin
NSAID / analgesic–anti-inflammatory · POM
Source-linked · Updated 03 Aug 2026 · Source: Clinical review pipeline
Kenya market
Wholesale / list prices where loaded
Risk first
Contraindications
- [From component Trypsin / Chymotrypsin] History of allergic reactions to any ingredient of the formulation, severe general infections, peptic ulcer, severe hepatic or renal disease, blood clotting disorders, avoid the use of anticoagulants.and hemorrhagic diathesis.
Precautions
- Lowest effective dose, shortest duration.
- GI protection (PPI) if high risk.
- CV risk (MI/stroke) with many NSAIDs — caution in known CVD.
- Monitor renal function in elderly, diuretic/ACEI/ARB users (triple whammy).
- Avoid combining multiple NSAIDs.
Point of care
Dosing
Adult
Dosing is indication-, age-, weight- and organ-function-specific for this INN. Do not use class averages for high-risk patients. Confirm the exact regimen in the current SmPC and Kenya Standard Treatment Guidelines. Typical professional workflow: (1) confirm indication, (2) check renal/hepatic function, (3) screen interactions/allergies, (4) select dose/route/duration, (5) define monitoring.
Paediatric
Paediatric dosing is weight- and age-based; use a paediatric formulary / SmPC. Do not extrapolate adult tablets without calculation.
Renal
Haemodynamically mediated AKI risk — high alert in volume depletion and renin-angiotensin blockade.
- CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Hepatic
Rare idiosyncratic hepatitis; more concern with prolonged high doses/diclofenac in some datasets.
Safety
Drug interactions
- Fixed-dose/multi-ingredient product.
- Clinical details partially inherited from component monographs: Trypsin / Chymotrypsin.
- Confirm combination SmPC for exact dosing.
Safety
Adverse effects
- Dyspepsia, nausea, fluid retention, raised BP.
- Serious: peptic ulcer/bleed, AKI, heart failure exacerbation, severe skin reactions, bronchospasm, hepatitis (rare).
Use
Indications
- Inflammation and pain in rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis.
- Clinical selection for Aceclofenac / Trypsin should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC.
- Class context: NSAID / analgesic–anti-inflammatory.
- Confirm site-specific dose, duration and monitoring before prescribing.
Pharmacology
Mode of action
Combination product.
Full mechanism text
Combination product. Component mechanism (Trypsin / Chymotrypsin): It lowers the intensity of inflammation, reduces the pain, helps in the resolution of edema, and exudate. It also facilitates the penetration of antibacterial agents in the affected areas.
ADME
Pharmacokinetics & PD
| Onset | 30–60 minutes |
|---|---|
| Duration | 4–12 hours (agent-dependent) |
| Route | ORAL / TOPICAL / RECTAL / IM (agent-dependent) |
| Elimination | of metabolites. Half-lives vary widely (ibuprofen short; naproxen longer; oxicams long). |
Kenya
Brands & prices
| Brand | Company | Pack | KES |
|---|---|---|---|
| No brands linked yet. | |||
Special populations
Pregnancy & lactation
Pregnancy
[Aceclofenac] Avoid in third trimester. Earlier pregnancy: use only if needed; prefer paracetamol first-line. [Trypsin] Use only if potential benefit justifies potential risk; prefer agents with better reproductive data when alternatives exist.
Lactation
[Aceclofenac] Short-course ibuprofen generally acceptable; avoid chronic high-dose/long half-life agents when possible. [Trypsin] Assess infant risk vs benefit of maternal therapy; prefer agents with lactation data.
Diet
Food & alcohol
- Food
- Food
Trust
Sources & disclaimer
Source: Clinical review pipeline
Last reviewed: 03 Aug 2026
Decision support only — not a substitute for clinical judgment, product SmPC, or Kenya STG/EML.